

Letter to the editor:

AN UPDATED REVIEW OF CUCURBITACINS AND THEIR BIOLOGICAL AND PHARMACOLOGICAL ACTIVITIES

Sun Ok Chung¹, Yong Joo Kim¹, Sang Un Park²

Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 305-764, Korea

¹ Department of Biosystems Machinery Engineering

² Department of Crop Science

* Corresponding author: E-mail: supark@cnu.ac.kr, Phone: +82-42-822-2631,
Fax: +82-42-822-2631

<http://dx.doi.org/10.17179/excli2015-283>

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence
(<http://creativecommons.org/licenses/by/4.0/>).

Dear Editor,

Cucurbitacins (Cus) are a class of highly oxidized tetracyclic triterpenoids that confer a bitter taste to cucurbits such as cucumber, melon, watermelon, squash, and pumpkin. To date, a large number of Cus and Cu-derived compounds have been isolated from the Cucurbitaceae family and from other species of the plant (Alghasham, 2013; Shang et al., 2014).

Cus have a range of biological and pharmacological activities that first attracted attention in the 1960s (Chen et al., 2012). Cucurbitacin B (CuB) and Cucurbitacin E (CuE) have been particularly widely studied (Lan et al., 2013). Recent reports have demonstrated that CuE has growth-inhibitory effects in the proliferation of many cancer cells such as bladder cancer, hepatocellular carcinoma, pancreatic cancer, breast cancer, and leukemia (Dong et al., 2010; Sørensen et al., 2012). CuB has been shown to have antimicrobial and anti-inflammatory activity. However, most reports on CuB focus on its anticancer activity. CuB inhibits the growth of human malignant cells, both in vitro and in vivo, and has been shown to be effective against breast cancer, head and neck squamous cell carcinoma, pancreatic cancer, hepatocellular carcinoma, osteosarcoma, and myeloid leukemia (Duangmano et al., 2010; Kausar et al., 2013; Guo et al., 2014a).

Consequently, natural and semisynthetic Cus are proposed as a promising source for the development of new drugs for the prevention and treatment of various cancers. Here, we summarize key recent studies that have evaluated the biological and pharmacological activities of Cu and its derivatives (Table 1).

Acknowledgements

This research was supported by Agriculture, Food and Rural Affairs Research Center Support Program, Ministry of Agriculture, Food and Rural Affairs.

Table 1: Recent studies on Cus and their biological and pharmacological activities

Key message	Reference
CuB dose dependently inhibited lung cancer cell proliferation by cell cycle inhibition and cyclin B1 downregulation. CuB was suggested to be a useful agent in the chemotherapy of lung cancer.	Zhang et al., 2014
CuD was shown to have a blocking effect in the G1 phase of the cell cycle in nonsmall lung cancer-N6 cells prior to apoptotic cell death. This study provided new insight into the mechanisms of proliferation arrest in tumor cells and potentially opens new ways of treatment to target tumor growth.	Jacquot et al., 2014
CuE significantly inhibited triple negative breast cancer (TNBC) cell growth by inducing cell cycle G2/M phase arrest and apoptosis. Thus, CuE was shown to be a viable compound for developing novel TNBC therapeutics.	Kong et al., 2014
Reactive oxygen species (ROS) were shown to mediate CuB-induced DNA damage, G2/M arrest, and apoptosis in K562 leukemia cells. This study provided novel mechanisms to better understand the underlying anticancer mechanisms of CuB.	Guo et al., 2014b
CuE inhibited cell proliferation and modulated the expression of cell cycle regulators in cancer cells using A549, Hep3B, and SW480 cells. This study provided a novel mechanism that may contribute to the antineoplastic effects of CuE in cancer cells.	Feng et al., 2014
This study explored the antiproliferation and cell cycle G2/M arrest induced by CuE in colorectal cancer (CRC) cells, and suggested that CuE may have antitumor activities in established CRC.	Hsu et al., 2014
CuB mediated breast tumor growth suppression associated with the inhibition of HER2, an oncogenic receptor implicated in HER2/integrin signaling. The results suggest novel targets of CuB in breast cancer, both <i>in vitro</i> and <i>in vivo</i> .	Gupta and Srivastava, 2014
CuB was shown to have potent chemopreventive activity for prostate cancer, and a novel antitumor mechanism of CuB via inhibition of ATP citrate lyase phosphorylation signaling in human cancer was reported.	Gao et al., 2014
This study provided new insights into the molecular mechanisms underlying Cul-mediated glioblastoma multiforme (GBM) cell death, and suggested Cul as an efficacious therapy for patients harboring GBM.	Yuan et al., 2014
Cucurbitacin IIb (Cullb) was shown to exhibit anti-inflammatory activity through modulating multiple cellular behaviors and signaling pathways, leading to the suppression of the adaptive immune response.	Wang et al., 2014
CuB showed potent inhibitory activity against hypoxia-inducible factor-1 (HIF-1) activation induced by hypoxia in various human cancer cell lines. The paper provided new insight into the anticancer mechanism of CuB's activity.	Ma et al., 2014
Cus were suggested as a new strategy to treat metabolic diseases and implicate STAT3 as a new target for the development of functional foods and drugs.	Seo et al., 2014
CuD extracted from <i>Trichosanthes kirilowii</i> was shown to be a potent therapeutic agent for breast cancer, blocking tumor cell proliferation and inducing apoptosis through the suppression of STAT3 activity.	Kim et al., 2013
Cul was suggested to have value as an adjunct chemotherapy agent.	Johnson et al., 2013
CuD was shown to initiate immunomodulating activity in macrophages, leading to inflammasome activation as well as enhancement of lipopolysaccharide signaling.	Song et al., 2013
CuE inhibited the growth of human breast cancer cells in a dose- and time-dependent manner, further indicating the potential clinical value of CuE for the prevention or treatment of human breast cancer.	Lan et al., 2013

Key message	Reference
CuE was shown to induce cell death by a mechanism that is not dependent on apoptosis induction, representing a promising anticancer agent for the prevention and treatment of human oral squamous cell carcinoma.	Hung et al., 2013
Both CuD and goyazensolide were shown to effectively inhibit the proliferation of neurofibromatosis type 2 (NF2)-deficient schwannoma and meningioma cells, suggesting that these natural compounds should be further evaluated as potential treatments for NF2-related tumors.	Spear et al., 2013
The induction of apoptosis and enhancement of autophagy was shown to contribute to the anti-inflammatory activity of Culla against inflammation-related diseases.	He et al., 2013
CuE was shown to display anti-inflammatory effects through the suppression of nuclear factor (NF)- κ B nuclear translocation, leading to a decreased expression of tumor necrosis factor (TNF)- α and interleukin (IL)-1 β in lipopolysaccharide-stimulated RAW 264.7 cells.	Qiao et al., 2013
The physical interaction of CuB with N-acetylcysteine and GSH in a cell-free system was demonstrated, suggesting that CuB interacts with and modulates cellular thiols to mediate its anticancer effects.	Kausar et al., 2013
Cucurbitacins I, D, and E were shown to present a potent cytotoxic activity toward the chondrosarcoma SW 1353 cell line, and are metabolized as sulfate and glucuronide conjugates.	Abbas et al., 2013
The combination of CuB at a relatively low concentration with either of the chemotherapeutic agents docetaxel or gemcitabine was shown to have a prominent antiproliferative activity against breast cancer cells without increased toxicity. This promising combination was suggested for therapeutic trials against breast cancer.	Aribi et al., 2013
CuB exhibited strong antiproliferative effects against breast cancer cells in a dose-dependent manner, and was shown to prominently alter the cytoskeletal network of breast cancer cells, inducing rapid morphologic changes and improper polymerization of the microtubule network.	Duangmano et al., 2012
CuE was shown to block breast cancer metastasis by suppressing tumor cell migration and invasion, and was suggested as a potential candidate for treating breast cancer metastasis.	Zhang et al., 2012

REFERENCES

Abbas S, Vincourt JB, Habib L, Netter P, Greige-Gerges H, Magdalou J. The cucurbitacins E, D and I: investigation of their cytotoxicity toward human chondrosarcoma SW 1353 cell line and their biotransformation in man liver. *Toxicol Lett.* 2013;216:189-99.

Alghasham AA. Cucurbitacins - a promising target for cancer therapy. *Int J Health Sci (Qassim).* 2013;7:77-89.

Aribi A, Gery S, Lee DH, Thoennissen NH, Thoennissen GB, Alvarez R, et al. The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. *Int J Cancer.* 2013;132:2730-7.

Chen X, Bao J, Guo J, Ding Q, Lu J, Huang M, et al. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. *Anticancer Drugs.* 2012;23:777-87.

Dong Y, Lu B, Zhang X, Zhang J, Lai L, Li D, et al. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. *Carcinogenesis.* 2010;31:2097-104.

Duangmano S, Dakeng S, Jiratchariyakul W, Suksamrarn A, Smith DR, Patmasiriwat P. Antiproliferative effects of cucurbitacin B in breast cancer cells: down-regulation of the c-Myc/hTERT/telomerase pathway and obstruction of the cell cycle. *Int J Mol Sci.* 2010;11:5323-38.

- Duangmano S, Sae-Lim P, Suksamrarn A, Domann FE, Patmasiriwat P. Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation. *BMC Complement Altern Med.* 2012; 12:185.
- Feng H, Zang L, Zhao ZX, Kan QC. Cucurbitacin-E inhibits multiple cancer cells proliferation through attenuation of Wnt/ β -catenin signaling. *Cancer Biother Radiopharm.* 2014;29:210-4.
- Gao Y, Islam MS, Tian J, Lui VW, Xiao D. Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth. *Cancer Lett.* 2014;349:15-25.
- Guo J, Wu G, Bao J, Hao W, Lu J, Chen X. Cucurbitacin B induced ATM-mediated DNA damage causes G2/M cell cycle arrest in a ROS-dependent manner. *PLoS One.* 2014a;9:e88140.
- Guo J, Zhao W, Hao W, Ren G, Lu J, Chen X. Cucurbitacin B induces DNA damage, G2/M phase arrest, and apoptosis mediated by reactive oxygen species (ROS) in leukemia K562 cells. *Anticancer Agents Med Chem.* 2014b;14:1146-53.
- Gupta P, Srivastava SK. Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. *Oncotarget.* 2014;5:1812-28.
- He J, Wang Y, Xu LH, Qiao J, Ouyang DY, He XH. Cucurbitacin IIa induces caspase-3-dependent apoptosis and enhances autophagy in lipopolysaccharide-stimulated RAW 264.7 macrophages. *Int Immunopharmacol.* 2013;16:27-34.
- Hsu YC, Huang TY, Chen MJ. Therapeutic ROS targeting of GADD45 γ in the induction of G2/M arrest in primary human colorectal cancer cell lines by cucurbitacin E. *Cell Death Dis.* 2014;5:e1198.
- Hung CM, Chang CC, Lin CW, Ko SY, Hsu YC. Cucurbitacin E as inducer of cell death and apoptosis in human oral squamous cell carcinoma cell line SAS. *Int J Mol Sci.* 2013;14:17147-56.
- Jacquot C, Rousseau B, Carbonnelle D, Chinou I, Malleter M, Tomasoni C, et al. Cucurbitacin-D-induced CDK1 mRNA up-regulation causes proliferation arrest of a non-small cell lung carcinoma cell line (NSCLC-N6). *Anticancer Res.* 2014;34:4797-806.
- Johnson MD, O'Connell MJ, Walter K. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis. *BMC Complement Altern Med.* 2013;13:303.
- Kausar H, Munagala R, Bansal SS, Aqil F, Vadhanam MV, Gupta RC. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets. *Cancer Lett.* 2013;332:35-45.
- Kim SR, Seo HS, Choi HS, Cho SG, Kim YK, Hong EH, et al. Trichosanthes kirilowii ethanol extract and cucurbitacin d inhibit cell growth and induce apoptosis through inhibition of stat3 activity in breast cancer cells. *Evid Based Complement Alternat Med.* 2013; 2013:975350.
- Kong Y, Chen J, Zhou Z, Xia H, Qiu MH, Chen C. Cucurbitacin E induces cell cycle G2/M phase arrest and apoptosis in triple negative breast cancer. *PLoS One.* 2014;9:e103760.
- Lan T, Wang L, Xu Q, Liu W, Jin H, Mao W, et al. Growth inhibitory effect of Cucurbitacin E on breast cancer cells. *Int J Clin Exp Pathol.* 2013;6:1799-805.
- Ma J, Zi Jiang Y, Shi H, Mi C, Li J, Xing Nan J, et al. Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1 α . *Eur J Pharmacol.* 2014; 723:46-54.
- Qiao J, Xu LH, He J, Ouyang DY, He XH. Cucurbitacin E exhibits anti-inflammatory effect in RAW 264.7 cells via suppression of NF- κ B nuclear translocation. *Inflamm Res.* 2013;62:461-9.
- Seo CR, Yang DK, Song NJ, Yun UJ, Gwon AR, Jo DG, et al. Cucurbitacin B and cucurbitacin I suppress adipocyte differentiation through inhibition of STAT3 signaling. *Food Chem Toxicol.* 2014;64:217-24.
- Shang Y, Ma Y, Zhou Y, Zhang H, Duan L, Chen H, et al. Plant science. Biosynthesis, regulation, and domestication of bitterness in cucumber. *Science.* 2014; 346:1084-8.
- Sörensen PM, Iacob RE, Fritzsche M, Engen JR, Brieher WM, Charras G, et al. The natural product cucurbitacin E inhibits depolymerization of actin filaments. *ACS Chem Biol.* 2012;7:1502-8.
- Song Y, Ding N, Kanazawa T, Yamashita U, Yoshida Y. Cucurbitacin D is a new inflammasome activator in macrophages. *Int Immunopharmacol.* 2013;17: 1044-50.
- Spear SA, Burns SS, Oblinger JL, Ren Y, Pan L, Kinghorn AD, et al. Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide. *Otol Neurotol.* 2013;34:1519-27.

Wang Y, Zhao GX, Xu LH, Liu KP, Pan H, He J, et al. Cucurbitacin IIb exhibits anti-inflammatory activity through modulating multiple cellular behaviors of mouse lymphocytes. *PLoS One*. 2014;9:e89751.

Yuan G, Yan SF, Xue H, Zhang P, Sun JT, Li G. Cucurbitacin I induces protective autophagy in glioblastoma in vitro and in vivo. *J Biol Chem*. 2014;289:10607-19.

Zhang M, Bian ZG, Zhang Y, Wang JH, Kan L, Wang X, et al. Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells. *Mol Med Rep*. 2014;10:2905-11.

Zhang T, Li J, Dong Y, Zhai D, Lai L, Dai F, et al. Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. *Breast Cancer Res Treat*. 2012;135:445-58.